A 5-year-old child with a known diagnosis of asthma presents to the emergency department with severe acute asthma (SpO2 88%, unable to complete sentences, use of all accessory muscles). Initial nebulized salbutamol and ipratropium have been given twice. What is the MOST APPROPRIATE next pharmacological addition?
- A IV aminophylline infusion as the most evidence-based addition for pediatric status asthmaticus
- B IV magnesium sulfate 25–75 mg/kg (max 2 g) over 20 minutes ✓
- C Inhaled heliox (helium-oxygen) to reduce turbulent airflow as the next step before IV magnesium
- D Oral montelukast as an add-on therapy for acute severe asthma unresponsive to bronchodilators
Explanation
In pediatric acute severe asthma unresponsive to initial combined bronchodilator therapy, IV magnesium sulfate (25–75 mg/kg, max 2 g over 20 minutes) is the next recommended step per GINA and BTS guidelines. Magnesium relaxes bronchial smooth muscle by inhibiting calcium-mediated bronchoconstriction and is safe in children. IV aminophylline has a narrow therapeutic index, frequent adverse effects, and weaker evidence compared to magnesium—it is now used less commonly and is not preferred. Heliox is an adjunct but lacks robust evidence as superior to magnesium. Montelukast has no role in acute severe asthma management.
Reference: Ghai Essential Pediatrics, 10th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.